SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-004376
Filing Date
2022-01-31
Accepted
2022-01-31 09:00:38
Documents
13
Period of Report
2022-01-31
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea154621-8k_gamidacell.htm   iXBRL 8-K 33433
2 PRESS RELEASE, DATED JANUARY 31, 2022, GAMIDA CELL PROVIDES KEY PROGRAM UPDATES ea154621ex99-1_gamidacell.htm EX-99.1 20686
  Complete submission text file 0001213900-22-004376.txt   237518

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gmda-20220131.xsd EX-101.SCH 3042
4 XBRL LABEL FILE gmda-20220131_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE gmda-20220131_pre.xml EX-101.PRE 22601
7 EXTRACTED XBRL INSTANCE DOCUMENT ea154621-8k_gamidacell_htm.xml XML 3754
Mailing Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484
Business Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484 97226595666
Gamida Cell Ltd. (Filer) CIK: 0001600847 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38716 | Film No.: 22571519
SIC: 2836 Biological Products, (No Diagnostic Substances)